ArticleFrontiers in genetics2026
WTAP-mediated m6A methylation of SOX2 affects lung adenocarcinoma malignancy via Wnt/β-catenin pathway.
Article in Frontiers in genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lung adenocarcinoma (LUAD) is one of the most common subtypes of lung cancer, characterized by high incidence and mortality rates. SOX2 is a transcription factor associated with the progression of various cancers. The role of the SOX2-Wnt/β-catenin signaling axis in LUAD has been previously reported; however, the upstream epitranscriptomic regulatory mechanisms governing SOX2, particularly the effects of m6A methylation on its expression, remain poorly elucidated. This study aims to investigate the role of SOX2 in the malignant progression of LUAD and its regulatory mechanisms, particularly its relationship with Wilms' tumor 1-associating protein (WTAP). Methods: Bioinformatics analysis was used to analyze LUAD transcriptome data in the TCGA database, and to analyze the differential expression of SOX2 and WTAP. LUAD patient samples were collected for validation. The A549 cell line was used to construct SOX2 knockdown and WTAP overexpression models. The cell phenotype changes, signaling pathway protein expression, m6A methylation levels, and mRNA stability were evaluated using qRT-PCR, Western blotting, colony formation assay, Transwell assay, flow cytometry, m6A Dot blot assay, and RNA stability assay. Data analysis was conducted using SPSS software, with a significance level set at Results: SOX2 was highly expressed in LUAD tissues, while WTAP expression was downregulated. Knockdown of SOX2 significantly inhibited the proliferation, migration, and invasion of LUAD cells and enhanced cell apoptosis ( Conclusion: This study reveals the oncogenic role of SOX2 in LUAD and its regulatory mechanism through the Wnt/β-catenin signaling pathway. It also elucidates the crucial role of WTAP in regulating SOX2 stability via m6A modification. These findings provide new potential therapeutic targets for LUAD, but further validation in animal models is needed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.